Tazemetostat Plus CHOP in 1L T-cell Lymphoma

NCT06692452 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Ipsen requested a temporary closure due to a safety concern.

Conditions

Lymphoma
Peripheral T Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Interventions

DRUG: Tazemetostat
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: Cytoxan
DRUG: Carmustine
DRUG: Etoposide
DRUG: Cytarabine
DRUG: Melphalan

Sponsor

Eric Jacobsen, MD

Collaborators

[object Object]